




2) Please replace claim 30 with the following claim:

30. A pharmaceutical composition for treating cancer comprising a compound and a pharmaceutically acceptable carrier, wherein the compound has the structure:



Bl  
a1  
cont




wherein R, R<sub>0</sub>, and R' are independently H, linear or branched chain alkyl, optionally substituted by hydroxy, alkoxy, carboxy, carboxaldehyde, linear or branched alkyl or cyclic acetal, fluorine, NR<sub>1</sub>R<sub>2</sub>, N-hydroximino, or N-alkoxyimino, wherein R<sub>1</sub> and R<sub>2</sub> are independently H, phenyl, benzyl, linear or branched chain alkyl; wherein Z is O, N(OR<sub>3</sub>) or N-NR<sub>4</sub>R<sub>5</sub>, wherein R<sub>3</sub>, R<sub>4</sub> and R<sub>5</sub> are independently H or a linear or branched chain alkyl; and wherein n is 0, 1, 2, or 3.

3) Please add the following new claims 60-96:

a2 59  
60.


The pharmaceutical composition of claim 30, wherein the compound has the structure:

Rule  
126




60  
61.

A pharmaceutical composition comprising a compound and a pharmaceutically acceptable carrier wherein the compound has the structure:



wherein R is hydrogen, methyl, ethyl, n-propyl, n-butyl, n-hexyl,  $\text{CH}_2\text{OH}$ ,  $(\text{CH}_2)_3\text{OH}$ , or



61  
62.

The pharmaceutical composition of claim 61, wherein R is hydrogen.

62  
63.

The pharmaceutical composition of claim 61, wherein R is ethyl.

63  
64.

The pharmaceutical composition of claim 61, wherein R is propyl.

64  
65.

The pharmaceutical composition of claim 61, wherein R is n-butyl.

65  
66.

The pharmaceutical composition of claim 61, wherein R is n-hexyl.

66  
67.


The pharmaceutical composition of claim 61, wherein R is  $\text{CH}_2\text{OH}$ .

67  
69.

The pharmaceutical composition of claim <sup>60</sup>61, wherein R is  $(CH_2)_3OH$ .


68  
70.

The pharmaceutical composition of claim <sup>60</sup>61, wherein R is



69  
71.

A pharmaceutical composition comprising a compound having the structure:




and a pharmaceutically acceptable carrier.

70  
72.

The pharmaceutical composition of claim <sup>69</sup>71, further comprising vinblastine.

71  
73.

A method of treating cancer in a subject suffering therefrom comprising administering to the subject a therapeutically effective amount of a compound having the structure:






A cont  
Rule 126

Sub  
B3

Sub  
B3

as  
cont  
Rule 126



wherein R, R<sub>0</sub>, and R' are independently H, linear or branched chain alkyl, optionally


Sp 126

substituted by hydroxy, alkoxy, carboxy, carboxaldehyde, linear or branched alkyl or cyclic acetal, fluorine,  $\text{NR}_1\text{R}_2$ , N-hydroximino, or N-alkoxyimino, wherein  $\text{R}_1$  and  $\text{R}_2$  are independently H, phenyl, benzyl, linear or branched chain alkyl; wherein Z is O,  $\text{N}(\text{OR}_3)$  or  $\text{N}-\text{NR}_4\text{R}_5$ , wherein  $\text{R}_3$ ,  $\text{R}_4$  and  $\text{R}_5$  are independently H or a linear or branched chain alkyl; and wherein n is 0, 1, 2, or 3.

72  
74.

The method of claim 71, comprising administering a therapeutically effective amount of a compound having the structure:

A 2  
cont  
Rule 126




73  
75.

A method of treating cancer in a subject suffering therefrom comprising administering to the subject a therapeutically effective amount of a compound having the structure:


Sp 126

Sub  
B4  
Cont

A2  
Cont  
Cont



wherein R is hydrogen, methyl, ethyl, n-propyl, n-butyl, n-hexyl, CH<sub>2</sub>OH, (CH<sub>2</sub>)<sub>3</sub>OH, or



74

76.

The method of claim <sup>73</sup>75, wherein in the compound R is hydrogen.

75

77.

The method of claim <sup>73</sup>75, wherein in the compound R is ethyl.

76

78.

The method of claim <sup>73</sup>75, wherein in the compound R is propyl.

77

79.

The method of claim <sup>73</sup>75, wherein in the compound R is n-butyl.

78

80.

The method of claim <sup>73</sup>75, wherein in the compound R is n-hexyl.

79

81.


The method of claim <sup>73</sup>75, wherein in the compound R is CH<sub>2</sub>OH.

80

82.

The method of claim <sup>73</sup>75, wherein in the compound R is (CH<sub>2</sub>)<sub>3</sub>OH.

81  
83. The method of claim <sup>73</sup>75, wherein in the compound R is




82  
84. The method of claim <sup>73</sup>75, wherein the effective amount is between about 0.001 mg/kg and about 25 mg/kg.

83  
85. The method of claim <sup>73</sup>75, wherein the cancer is a solid tumor.

84  
86. The method of claim <sup>73</sup>75, wherein the cancer is breast cancer, melanoma, leukemia or ovarian cancer.

85  
87. The method of claim <sup>73</sup>75, wherein the cancer is an MDR-resistant cancer.

86  
88. A method of treating cancer in a subject suffering therefrom comprising administering to the subject a therapeutically effective amount of a compound having the structure:



87  
89. The method of claim <sup>86</sup>88, wherein the effective amount is between about 0.001 mg/kg and about 1 mg/kg.